@FiercePharma: ICYMI: Boehringer looks for Pradaxa boost from now FDA-approved antidote. Article | Follow @FiercePharma
@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. More | Follow @EricPFierce
@CarlyHFierce: Shire's eye drug setback gives Allergan's Restasis a temporary reprieve. Story | Follow @CarlyHFierce
> Danish drugmaker Lundbeck used additional data to persuade cost-effectiveness watchdogs in England to back its new antidepressant Brintellix. Report
> Drugmakers prevailed in their latest fight against 340B hospital discounts on orphan drugs in nonorphan indications. Report
> Sprout Pharmaceuticals rolled out the controversial female libido drug Addyi on Saturday, and analysts are saying that safety issues with the med could spur development of better follow-up drugs. Report
> Sanofi ($SNY) and Regeneron ($REGN) rolled out their cholesterol-fighting PCSK9 drug Praluent in the U.K., going up against Amgen's ($AMGN) Repatha, which launched there last month. Report
> Allergan ($ACT) wrapped up its buyout of the eye care company AqueSys and its experimental glaucoma-focused device. Report
Medical Device News
@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev
@VarunSaxena2: #TCT15: Startup's minimally invasive mitral valve repair tech shows promise in feasibility study. Story | Follow @VarunSaxena2
@EmilyWFierce: ICYMI: European investor shells out $118M for DNA testing outfit to boost animal Dx offerings. Article | Follow @EmilyWFierce
> Sientra slides amid implant manufacturing fallout in Brazil. Article
> FDA commissioner nominee stresses need to improve combination product reviews. Story
Biotech News
@FierceBiotech: ICYMI Friday: Biotech notches another $2B VC quarter, but can it last? Story | Follow @FierceBiotech
@JohnCFierce: Shire hit with another setback as FDA rejects top pipeline drug- Does anyone think that Ornskov is a good CEO? Article | Follow @JohnCFierce
@DamianFierce: Not often a company issues two separate statements on a single drug rejection. Not often a company issues two separate statements on a single drug rejection. More | Follow @DamianFierce
> Genocea halts its antibiotic vaccine program after a Phase II failure. Story
> Basilea plots $190M IPO on Nasdaq as it circles a PhIII antibiotic study. Article
Animal Health News
> European investor shells out $118M for DNA testing outfit to boost animal Dx offerings. Story
> Dog study validates Blaze 'tumor paint' for guiding surgery. Report
> Nexvet launches field trial of treatment for feline osteoarthritis. More
> Ceva, Harrisvaccines nab USDA contracts for bird flu vaccines. Article
> Dogs with cleft palates add to knowledge of condition in children. Story
Biotech IT News
> Venter's Human Longevity starts $50,000 health testing service. News
> LabKey lands data-management deal with 100,000 Genomes Project. More
> EU consortium creates large toxin database for drug discovery. Report
> Scripps teams up to apply genomics to stem cell quality control. Story
> 23andMe raises $115M as investors buy into data-driven drug discovery vision. Article
Pharma Marketing News
> One year after FDA nod, Eli Lilly's Trulicity launches first consumer campaign. Item
> Merck KGaA exits 'sea of sameness' with futuristic rebrand. Editor's corner
> Pacira sues for free speech; FDA pulls off-label warning letter. What gives? More
> Bayer consumer biz on digital agency hunt, in shift from 'TV-centric' to 'channel-agnostic.' Article
> Influential cancer group releases first batch of affordability info on cancer meds. Item
And Finally... The Novartis ($NVS) cancer drug Tasigna delivered "meaningful clinical improvements" in 10 of 11 Parkinson's disease patients in an early-stage trial. Report